Literature DB >> 7523729

Impact of radical prostatectomy in the management of clinically localized disease.

D F Paulson1.   

Abstract

The cancer specific death rate following radical prostatectomy in patients with organ confined and specimen confined disease was 10% at 13.5 years, less than the noncancer death rate of 20% for patients in these disease extent categories. The median age of all patients in these categories was 65 years. Cancer remains the dominate cause of death in patients with margin-positive disease, being 40% at 13.5 years. Disease detected by prostate specific antigen (PSA) rather than digital rectal examination appears to be of smaller volume and to have a higher probability of negative margins. Data argue that early detection of PSA will shift patients to a more favorable disease category at surgical intervention. Disease recurrence or persistence by PSA detection seems to precede clinical detection of disease by 3 to 5 years. Disease recurrence by PSA detection does not predict survival outcome, probably does not differentiate between local and distant microscopic recurrence, and is not predictive of biological aggressiveness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523729     DOI: 10.1016/s0022-5347(17)32395-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Laparoscopic prostatectomy: where do we stand?

Authors:  Mesut Remzi; Bob Djavan
Journal:  Rev Urol       Date:  2002

Review 2.  MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results.

Authors:  Christiaan G Overduin; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

3.  The influence of extent of surgical margin positivity on prostate specific antigen recurrence.

Authors:  R E Emerson; M O Koch; T D Jones; J K Daggy; B E Juliar; L Cheng
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 4.  Pathological changes in prostate lesions after androgen manipulation.

Authors:  R Montironi; C C Schulman
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

Review 5.  Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

Authors:  M C Beduschi; R Beduschi; J E Oesterling
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 6.  Therapy of recurrent disease after radical prostatectomy in 2007.

Authors:  Rudolf Schwarz; Markus Graefen; Andreas Krüll
Journal:  World J Urol       Date:  2007-02-28       Impact factor: 4.226

7.  Experience with radical perineal prostatectomy in the treatment of localized prostate cancer.

Authors:  Evi Comploj; Armin Pycha
Journal:  Ther Adv Urol       Date:  2012-06

8.  Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men.

Authors:  Cheryn Song; Taejin Kang; Jae Y Ro; Moo-Song Lee; Choung-Soo Kim; Hanjong Ahn
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

9.  Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.

Authors:  C Selli; R Montironi; A Bono; F Pagano; F Zattoni; A Manganelli; F P Selvaggi; G Comeri; G Fiaccavento; S Guazzieri; A Lembo; S Cosciani-Cunico; D Potenzoni; G Muto; R Mazzucchelli; A Santinelli
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

10.  Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Authors:  Rubén Algarra; Mateo Hevia; Antonio Tienza; Imanol Merino; José María Velis; Javier Zudaire; José Enrique Robles; Ignacio Pascual
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.